TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05653258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib 100 MG
Description: 100 mg of dasatinib (D) daily for 3 consecutive days plus quercetin (Q) for the same 3 consecutive days, followed by a 25-day (+/- 2 day) no-drug period to complete a single round. This will be repeated twice more until completing 3 rounds total in approximately 10 consecutive weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quercetin 1000mg
Description: Quercetin (Q) (4) 250 mg capsules daily (total 1000 mg daily) plus dasatinib (D) same 3 consecutive days, followed by a 25-day (+/- 2 day) no-drug period to complete a single round. This will be repeated twice more until completing 3 rounds total in approximately 10 consecutive weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive a placebo (methylcellulose) to provide a similar mass, number of tablets/ capsules, and frequency as the senolytic arm.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Abdominal adipose tissue biopsy
Description: All participants will undergo baseline biopsies of subcutaneous abdominal adipose tissue for cellular/molecular profiling via snRNA-seq
Study: NCT05862987

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrogen rich water
Description: Hydrogen-rich water with molecular hydrogen concentration 0.9 ppm.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tap water with molecular hydrogen concentration 0.0 ppm.
Study: NCT05653258

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal adipose tissue biopsy
Description: All participants will undergo baseline biopsies of subcutaneous abdominal adipose tissue for cellular/molecular profiling via snRNA-seq

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Abdominal adipose tissue biopsy
Description: All participants will undergo baseline biopsies of subcutaneous abdominal adipose tissue for cellular/molecular profiling via snRNA-seq
Study: NCT01546012

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HYABAK®
Description: Hyaluronic Acid eye drops CE marked, packaged in multidose ABAK® container (preservative free)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HYLO-COMOD®
Description: Hyaluronic Acid eye drops CE marked, packaged in multidose COMOD® container (preservative free)
Study: NCT04877743

Intervention type: OTHER
Intervention: None (Observational study)
Description: The main data sources for the study will be participants and their medical records. Vaccination details will be verified by a vaccination card, batch/lot number, and/or using a regional vaccination register. Participants will report all study outcomes using the study app, web portal, or call centre. Participants can also select a proxy to communicate on their behalf: a caregiver, family member, or other trusted individual. Participants will be asked for an emergency contact in case of death or incapacity.
Study: NCT04680676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: BI 730357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: BI 730357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: BI 730357

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04741698

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Propranolol 2mg IV
Study: NCT06130527

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nicardipine
Description: Following the intubation, the infusion was initiated by using an infusion device (Orchestra Base Primea, Fresenius Kabi) with an i.v. dose of 1.0 µg/kg/min iv in Group N. The targeted MAP was determined as 50-65 mmHg and drug doses were increased until the targeted MAP was achieved In Group N. Nicardipine infusion will be increased by titration in groups with MAP above 65 mm/Hg for more than 5 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Infusion was administered i.v. using an infusion device (Orchestra Base Primea, Fresenius Kabi). In Group R, the dose will start at 0.05 µg/kg/min following intubation. The target MAP was determined as 50-65 mmHg and drug doses will be increased until the target MAP is reached. HR more than 120 seconds and less than 45 beats/min will be considered as bradycardia and the remifentanil dose will be reduced. If response is unsatisfactory, 0.5 mg Atropine i.v. will be implemented. Nicardipine and Remifentanil infusions in groups will be increased by titration if MAP rises above 65 mm/Hg for more than 5 minutes.
Study: NCT04758910

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Oxygen Therapy
Description: A 30-minute spontaneous breathing trial using high flow oxygen therapy via tracheostomy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: T-piece
Description: A 30-minute spontaneous breathing trial using T-piece via tracheostomy.
Study: NCT05753527

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Relaxation Exercises
Description: Deep abdominal breathing will be done three times and the breath will be given slowly. The fists will be clenched, keep the fists clenched in this way for 7-10 seconds, and then release them for 15-20 seconds. By opening the arms to the side and locking the elbows, the triceps muscle will be stretched and relaxed. The forehead muscles by raising the eyebrows The eyes will be closed and relaxed. The mouth will be opened and closed. The head will be stretched back and relaxed. The shoulders will be lifted and relaxed. Both hips will be tightened and relaxed by bringing them closer together. The thigh muscles will be tightened and relaxed.
Study: NCT05391542

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aligning archwires
Description: At the day of bonding, 0.016-inch archwire will be placed for the TuNT group. Eight weeks later it will be replaced by the 0.018-inch archwire for another eight weeks. While, for the CuNT group, 0.014-inch archwire will be placed at the day of bonding and eight weeks later it will be replaced by the 0.018-inch archwire for another eight weeks. Archwires will be tied to the bracket by elastomeric modules which will be changed every 4 weeks. A good-quality alginate impression for the lower arch should be taken pre-treatment and after 4, 8, 12 and 16 weeks and a stone study model is obtained. Periapical X-ray for the mandibular central incisors will be taken pre-treatment and after 16 weeks. The participants will be provided by a visual analog scale (0-10) to record their pain perception during the first week after each wire placement.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aligning archwires
Description: At the day of bonding, 0.016-inch archwire will be placed for the TuNT group. Eight weeks later it will be replaced by the 0.018-inch archwire for another eight weeks. While, for the CuNT group, 0.014-inch archwire will be placed at the day of bonding and eight weeks later it will be replaced by the 0.018-inch archwire for another eight weeks. Archwires will be tied to the bracket by elastomeric modules which will be changed every 4 weeks. A good-quality alginate impression for the lower arch should be taken pre-treatment and after 4, 8, 12 and 16 weeks and a stone study model is obtained. Periapical X-ray for the mandibular central incisors will be taken pre-treatment and after 16 weeks. The participants will be provided by a visual analog scale (0-10) to record their pain perception during the first week after each wire placement.
Study: NCT05542303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZB001 for injection
Description: Dose Cohort3 (20mg/kg) ZB001 of single IV injection
Study: NCT05772858

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training on CIFFTA competencies using Family Therapy Training and Implementation Platform (FTTIP)
Description: An Innovative Web-based Tool to train mental health therapists in family therapy competencies with animated families and provided recorded video responses to receive feedback from trainers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training on CIFFTA competencies using Training and Coaching as Usual (TCAU).
Description: Therapists receive training using the traditional face to-face training method for 2.5 days followed by coaching.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Culturally Informed and Flexible Family-Based Treatment for Adolescents (CIFFTA).
Description: CIFFTA has three major components: Family Therapy, Individual Therapy, and Psycho-educational Modules, delivered over 16 weeks in a two session (60 minutes each) per week format. One session will typically be a family session which may include Family Therapy or Psychoeducational modules designed for the family or parents alone. The other session is typically with the adolescent alone which may include individual treatment or Psycho-educational modules designed for the adolescent.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Agency Readiness Consultation- Family Therapy Training and Implementation Platform (FTTIP)
Description: The FTTIP agency readiness work begins with a pre-recorded FTTIP introduction webinar presented separately to each agency which presents overall goals of the project and the different FTTIP components, and key decisions agencies often make when seeking to sustain a new EBT.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Agency Engagement and Orientation as Usual
Description: Work with the agency leaders will consist of the traditional engagement of the leadership so that they agree to collaboration with the study team, with the training team, and with the study procedures.
Study: NCT05167149

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carbon nanoparticles
Description: After pneumoperitoneum is established and laparoscopic instruments are prepared, according to National Comprehensive Cancer Network (NCCN) guidelines, 1ml diluted ICG solution (25 mg /10 ml) is injected into the submucosa around tumor at 3 and 9 o'clock of the cervix (2ml totally) with 1ml syringe. ICG should be slowly injected to avoid drug leakage. Intratumoral and deep cervical stroma injection should be avoided. The retroperitoneum is dissected immediately after injection under the multimodel observation of fluorescence laparoscopy. Search the fluorescent labeled lymphatics from bilateral parametrium to iliac vessels. The diffusion of ICG is rapid , and it is easy to spread to the next stations lymph nodes. The first fluorescent labeled lymph nodes on each lymphatic drainage pathway are identified as SLNs, other than all fluorescent lymph nodes. All detectable SLNs and enlarged or suspicious nodes regardless of mapping are resected for pathological examination alone.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine green
Description: After pneumoperitoneum is established and laparoscopic instruments are prepared, according to NCCN guidelines, 0.5ml(25mg) carbon nanoparticle solution (the dose was from our retrospective study) is injected into the submucosa around tumor at 3 and 9 o'clock of the cervix (1ml totally) with 1ml syringe. Carbon nanoparticle should be slowly injected to avoid drug leakage. Intratumoral and deep cervical stroma injection should be avoided. The retroperitoneum is dissected immediately after injection. Search the black lymphatics from bilateral parametrium to iliac vessels. Because there is no fluorescence penetration as ICG, the black lymphatic vessels should be dissected carefully.The first black lymph nodes on each lymphatic drainage pathway are identified as SLNs, other than all black lymph nodes. All detectable SLNs and enlarged or suspicious nodes regardless of mapping are resected for pathological examination alone.
Study: NCT05064007

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A: 40 Hz music
Description: The participant will listen to the 40 Hz music playlist one hour each day, 5 days a week for 4 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A: 40 Hz music
Description: The participant will listen to the 40 Hz music playlist one hour each day, 5 days a week for 4 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A: 40 Hz music
Description: The participant will listen to the 40 Hz music playlist one hour each day, 5 days a week for 4 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: B: 40 Hz sound
Description: The participant will listen to the 40 Hz sound playlist one hour each day, 5 days a week for 4 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: B: 40 Hz sound
Description: The participant will listen to the 40 Hz sound playlist one hour each day, 5 days a week for 4 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: B: 40 Hz sound
Description: The participant will listen to the 40 Hz sound playlist one hour each day, 5 days a week for 4 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: C: Preferred music
Description: The participant will listen to the preferred music playlist one hour each day, 5 days a week for 4 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: C: Preferred music
Description: The participant will listen to the preferred music playlist one hour each day, 5 days a week for 4 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: C: Preferred music
Description: The participant will listen to the preferred music playlist one hour each day, 5 days a week for 4 weeks
Study: NCT05302193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calm measurement of blood pressure and heart rate (before physical activity)
Description: Simultaneous blood pressure and heart rate measurements at minutes 2 and 5.5 of the experiment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Five minutes of physical activity, between times 7.5 min and 12.5 min of the experimental part. Riding on a spinning ergometer with a standardized load of 1 W/kg.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calm measurement of blood pressure and heart rate (after physical activity)
Description: Simultaneous blood pressure and heart rate measurements at times 15.5, 17, 20.5 and 22 minutes of the experimental part.
Study: NCT05805488

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sachet
Description: consume 1 sachet per day
Study: NCT05488795

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Team-Based Home Blood Pressure Monitoring
Description: Implementation of best practices for hypertension control using a practice wide team-based home blood pressure monitoring intervention

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Team-Based Home Blood Pressure Monitoring
Description: Implementation of best practices for hypertension control using a practice wide team-based home blood pressure monitoring intervention

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Team-Based Home Blood Pressure Monitoring
Description: Implementation of best practices for hypertension control using a practice wide team-based home blood pressure monitoring intervention
Study: NCT05020808

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: NEAA
Description: Food grade mixture of non-essential amino acids in powdered form to be dissolved in water. Supplied by Marigot Ltd, Cork, Ireland

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PPI
Description: Food grade plant (legume - Fava) protein isolate to be dissolved in water. Supplied by Marigot Ltd, Cork, Ireland
Study: NCT05805488

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TCI904 sachet
Description: consume 1 sachet per day
Study: NCT05940987

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone-based smoking cessation intervention
Description: Participants who allocate to the intervention group will receive regular phone-based smoking cessation intervention by professional team.
Study: NCT05388968

Intervention type: BIOLOGICAL
Intervention: Metatranscriptomic
Description: Analysis with metatranscriptomic next generation sequencing of trophoblast obtained by chorionic villi sampling

Intervention type: BIOLOGICAL
Intervention: Metatranscriptomic
Description: Analysis with metatranscriptomic next generation sequencing of trophoblast obtained by chorionic villi sampling

Intervention type: BIOLOGICAL
Intervention: Metatranscriptomic
Description: Analysis with metatranscriptomic next generation sequencing of trophoblast obtained by chorionic villi sampling

Intervention type: DIAGNOSTIC_TEST
Intervention: Specific microbiologic diagnosis
Description: If a microorganism is detected by metatranscriptomic NGS, specific diagnosis (PCR and serology) will be done in maternal and neonatal samples (blood, urine, saliva)

Intervention type: DIAGNOSTIC_TEST
Intervention: Specific microbiologic diagnosis
Description: If a microorganism is detected by metatranscriptomic NGS, specific diagnosis (PCR and serology) will be done in maternal and neonatal samples (blood, urine, saliva)

Intervention type: DIAGNOSTIC_TEST
Intervention: Specific microbiologic diagnosis
Description: If a microorganism is detected by metatranscriptomic NGS, specific diagnosis (PCR and serology) will be done in maternal and neonatal samples (blood, urine, saliva)
Study: NCT06425341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5635 Injection
Description: HRS-5635 Injection low dose administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5635 Injection
Description: HRS-5635 Injection medium dose administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5635 Injection
Description: HRS-5635 Injection high dose administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5635 Injection
Description: HRS-5635 Injection lowest dose administered by subcutaneous injection
Study: NCT05638217

Intervention type: COMBINATION_PRODUCT
Intervention: Silver diamine fluoride 38% followed by Sodium fluoride varnish 5%
Description: 1)Completely drying of the affected area 2)10 microliters of silver diamine fluoride 38% (CaviGuard®) will be placed on the affected area 3)The affected area should be immediately covered with 20 microliters of fluoride varnish 5% (CaviGuard®) 4)Repeat steps 1-3 one or two more times for large caries at intervals of at least 2 days apart 5)Follow up evaluation of treatment success visits will be conducted at 6 and 12 months from the initial treatment.~NOTE: This is a single intervention using the device registered as Caviguard® to apply both products (Silver diamine fluoride 38% followed by Sodium fluoride varnish 5% (®)) in sequence.
Study: NCT06427642

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mononuclear cells
Description: UCB-MNCs are obtained from umbilical cord blood by density gradient centrifugation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mononuclear cells
Description: UCB-MNCs are obtained from umbilical cord blood by density gradient centrifugation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mononuclear cells
Description: UCB-MNCs are obtained from umbilical cord blood by density gradient centrifugation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mild hypothermia therapy
Description: Mild hypothermia therapy via hypothermia therapy apparatus

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mild hypothermia therapy
Description: Mild hypothermia therapy via hypothermia therapy apparatus

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Breathing support technique
Description: Breathing support via ventilator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breathing support technique
Description: Breathing support via ventilator

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total parenteral nutrition
Description: Liquid nutrition injected directly into the bloodstream

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition
Description: Liquid nutrition injected directly into the bloodstream
Study: NCT05294146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofazimine
Description: All participants will receive an (experimental) oral loading dose regimen of 300 mg clofazimine once daily (= 3 capsules of 100 mg) for 4 weeks. Afterwards, all participants will continue with a standard oral dose of 100 mg clofazimine once daily (= 1 capsule of 100 mg) until a total 4 months of treatment with CFZ.~Blood samples will be taken at Day 28 (+/- 2 days), Day 29 (Day 28 +1) and after 4 months of treatment to assess the pharmacokinetics of CFZ, both with the loading dose and the standard dose. In addition, the safety/tolerability of CFZ will monitored.
Study: NCT06247800

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Device
Description: A virtual reality headset is a heads-up display that allows users to interact with simulated environment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Without virtual reality
Description: Patients undergoing intercostal chest drain without the use VR device
Study: NCT05439772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Patient will take one dissolvable tablet of ondansetron prior to initiating PEG consumption.
Study: NCT05632354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osivelotor
Description: Osivelotor
Study: NCT06001385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV or PO pre-transplant as part of conditioning regimen